Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Humacyte (Nasdaq: HUMA) has announced an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase up to an additional 15% of offered shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company act as lead managers.
The commercial-stage biotechnology platform company, focused on developing universally implantable bioengineered human tissues, intends to use the proceeds to fund:
- Commercialization of SYMVESS™ in vascular trauma indication
- Development of product candidates in pipeline
- Working capital and general corporate purposes
The offering will be made through a shelf registration statement previously filed and declared effective by the SEC. The final size, terms, and completion of the offering remain subject to market conditions.
Humacyte (Nasdaq: HUMA) ha annunciato un'offerta pubblica sottoscritta delle sue azioni ordinarie, con l'intenzione di concedere agli underwriter un'opzione di acquisto di ulteriori 15% delle azioni offerte per un periodo di 30 giorni. TD Cowen, Barclays e BTIG stanno fungendo da gestori congiunti dell'offerta, mentre H.C. Wainwright & Co. e The Benchmark Company agiscono come gestori principali.
La società, attiva nella fase commerciale della biotecnologia e focalizzata sullo sviluppo di tessuti umani bioingegnerizzati universalmente impiantabili, intende utilizzare i proventi per finanziare:
- La commercializzazione di SYMVESS™ per l'indicazione di trauma vascolare
- Lo sviluppo di candidati a prodotto nel pipeline
- Capitale circolante e scopi aziendali generali
L'offerta sarà effettuata tramite una dichiarazione di registrazione a scaffale precedentemente depositata e dichiarata efficace dalla SEC. La dimensione finale, i termini e il completamento dell'offerta rimangono soggetti alle condizioni di mercato.
Humacyte (Nasdaq: HUMA) ha anunciado una oferta pública suscrita de sus acciones ordinarias, con planes de otorgar a los suscriptores una opción de 30 días para comprar hasta un 15% adicional de las acciones ofrecidas. TD Cowen, Barclays y BTIG están actuando como gerentes conjuntos de la oferta, mientras que H.C. Wainwright & Co. y The Benchmark Company actúan como gerentes principales.
La empresa de biotecnología en etapa comercial, enfocada en desarrollar tejidos humanos bioingenierizados universalmente implantables, tiene la intención de utilizar los ingresos para financiar:
- La comercialización de SYMVESS™ en la indicación de trauma vascular
- El desarrollo de candidatos a producto en la cartera
- Capital de trabajo y propósitos corporativos generales
La oferta se realizará a través de una declaración de registro en estante previamente presentada y declarada efectiva por la SEC. El tamaño final, los términos y la finalización de la oferta están sujetos a las condiciones del mercado.
Humacyte (Nasdaq: HUMA)는 일반 주식의 공모를 발표했으며, 인수인에게 제공된 주식의 최대 15%를 추가로 구매할 수 있는 30일 옵션을 부여할 계획입니다. TD Cowen, Barclays, BTIG가 공동 주관사로 활동하고 있으며, H.C. Wainwright & Co.와 The Benchmark Company가 주요 주관사로 활동하고 있습니다.
상업 단계의 생명공학 플랫폼 회사로, 보편적으로 이식 가능한 생체공학적 인간 조직 개발에 집중하고 있는 Humacyte는 수익금을 다음과 같은 용도로 사용할 계획입니다:
- 혈관 외상 적응증에서 SYMVESS™의 상용화
- 파이프라인 내 제품 후보 개발
- 운영 자본 및 일반 기업 목적
이번 공모는 SEC에 의해 이전에 제출되어 승인된 선등록 성명을 통해 이루어질 것입니다. 최종 규모, 조건 및 공모 완료는 시장 상황에 따라 달라질 수 있습니다.
Humacyte (Nasdaq: HUMA) a annoncé une offre publique souscrite de ses actions ordinaires, avec l'intention d'accorder aux souscripteurs une option de 30 jours pour acheter jusqu'à 15% d'actions supplémentaires offertes. TD Cowen, Barclays et BTIG agissent en tant que gestionnaires co-dirigeants, tandis que H.C. Wainwright & Co. et The Benchmark Company agissent en tant que gestionnaires principaux.
La société de biotechnologie en phase commerciale, axée sur le développement de tissus humains bio-ingénierés universellement implantables, a l'intention d'utiliser les produits pour financer :
- La commercialisation de SYMVESS™ pour l'indication de traumatisme vasculaire
- Le développement de candidats à des produits dans le pipeline
- Le fonds de roulement et les objectifs d'entreprise généraux
L'offre sera réalisée par le biais d'une déclaration d'enregistrement en étagère précédemment déposée et déclarée efficace par la SEC. La taille finale, les termes et l'achèvement de l'offre restent soumis aux conditions du marché.
Humacyte (Nasdaq: HUMA) hat eine unterzeichnete öffentliche Angebotsaktion ihrer Stammaktien angekündigt, mit dem Plan, den Underwritern eine 30-tägige Option zu gewähren, um bis zu 15% zusätzlicher angebotener Aktien zu erwerben. TD Cowen, Barclays und BTIG fungieren als gemeinsame Buchführungsmanager, während H.C. Wainwright & Co. und The Benchmark Company als Hauptmanager tätig sind.
Das kommerziell tätige Biotechnologieunternehmen, das sich auf die Entwicklung universell implantierbarer bioengineerter menschlicher Gewebe konzentriert, beabsichtigt, die Erlöse zur Finanzierung von:
- Die Kommerzialisierung von SYMVESS™ bei der Indikation für vaskuläre Traumata
- Die Entwicklung von Produktkandidaten in der Pipeline
- Betriebskapital und allgemeine Unternehmenszwecke
Das Angebot wird über eine zuvor eingereichte und von der SEC genehmigte Shelf-Registrierungserklärung durchgeführt. Die endgültige Größe, die Bedingungen und der Abschluss des Angebots unterliegen den Marktbedingungen.
- Funding secured for SYMVESS™ commercialization in vascular trauma
- Additional capital for product pipeline development
- Strong underwriting team including major financial institutions
- Potential shareholder dilution from new stock issuance
- Uncertain offering terms and size
- Market-dependent completion risk
Insights
Humacyte's announced common stock offering represents a strategic capital raise with potential dilutive effects for existing shareholders. The absence of specific details regarding offering size and pricing creates uncertainty about the magnitude of dilution, though the 30-day underwriter option to purchase an additional 15% of shares indicates the company aims to maximize its fundraising capacity.
The company has clearly outlined three priorities for the proceeds: commercialization of SYMVESS™ in vascular trauma, pipeline development, and general working capital. This allocation strategy balances immediate commercial needs with longer-term growth investments, typical for biotech companies transitioning from development to commercialization phases.
The participation of established underwriters including TD Cowen, Barclays, and BTIG lends credibility to this financing event. For a company with a
For investors, this offering presents the classic biotech financing dilemma: near-term ownership dilution versus enhanced financial capacity to execute on commercial opportunities. The pre-existence of a shelf registration statement from September 2022 suggests this capital raise has been contemplated as part of Humacyte's longer-term financing strategy rather than an urgent cash requirement.
Humacyte's decision to raise capital at this juncture signals the company's transition into a critical commercialization phase for SYMVESS™ in vascular trauma. The prioritization of commercialization funding indicates management's confidence in the market opportunity and recognition of the substantial resources required for a successful product launch.
Launching bioengineered human tissue products requires significant investment in several key areas: manufacturing scale-up to commercial levels, development of specialized distribution channels, healthcare provider education, and establishment of reimbursement pathways. These commercialization activities typically demand substantial capital beyond what's needed for research and development phases.
The company's platform technology for developing universally implantable, bioengineered human tissues at commercial scale represents an innovative approach with potential applications beyond vascular trauma. The allocation of proceeds to pipeline development suggests a long-term strategy to leverage this platform across multiple indications.
For Humacyte to successfully commercialize SYMVESS™, adequate capitalization is essential, making this offering a logical step despite dilutive effects. The company appears to be making a calculated decision to ensure sufficient resources for proper market entry rather than attempting to commercialize with constrained capital, which often leads to suboptimal outcomes in the biotech sector.
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional
TD Cowen, Barclays and BTIG are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates in Humacyte’s pipeline and for working capital and general corporate purposes.
A shelf registration statement on Form S-3 (No. 333-267225) was previously filed with the Securities and Exchange Commission (the “SEC”) on September 1, 2022 and declared effective by the SEC on September 9, 2022. The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (833) 297-2926, or by email at TD.ECM_Prospectus@tdsecurities.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com; or BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555 or by email at ProspectusDelivery@btig.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of acellular tissue engineered vessels (“ATEVs”), are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (“AV”) access for hemodialysis, and peripheral artery disease (“PAD”). A Biologics License Application for the ATEV in the vascular trauma indication was approved by the U.S. Food and Drug Administration (“FDA”) in December 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (“RMAT”) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Humacyte believes that it has a reasonable basis for each forward-looking statement contained in this press release, Humacyte cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which Humacyte cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and success of the proposed offering; whether Humacyte will be able to raise capital through the sale of shares of common stock in the offering; the anticipated use of proceeds from the proposed offering; Humacyte’s plans and ability to commercialize its ATEV in the United States under the brand name SYMVESS in vascular trauma repair; the statements regarding the initiation, timing, progress, and results of Humacyte’s preclinical and clinical trials; the anticipated characteristics and performance of its ATEVs; Humacyte’s ability to successfully complete, preclinical and clinical trials for its ATEVs; the anticipated benefits of the ATEV relative to existing alternatives; the anticipated commercialization of the ATEVs and Humacyte’s ability to manufacture at commercial scale; the implementation of Humacyte’s business model and strategic plans for its business; and the timing or likelihood of regulatory filings, acceptances and approvals. Humacyte cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in Humacyte’s Annual Report on Form 10-K for the year ended December 31, 2023, Humacyte’s quarterly report on Form 10-Q for the quarter ended September 30, 2024, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Humacyte or any other person that Humacyte will achieve its objectives and plans in any specified time frame, or at all. Except as required by law, Humacyte has no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing Humacyte’s views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte
FAQ
What is the purpose of Humacyte's (HUMA) public stock offering in March 2025?
Who are the underwriters for Humacyte's (HUMA) 2025 stock offering?
What is the additional purchase option in HUMA's March 2025 offering?
How will Humacyte use the proceeds from its 2025 stock offering?
